Heparibene Na (Heparin)

Heparibene Na is indicated for several clinical situations where inhibition of clot formation is required.

• Prevention and treatment of deep vein thrombosis (DVT) in at‑risk patients.
• Prevention and treatment of pulmonary embolism (PE) following DVT or as primary therapy.
• Prophylaxis of thromboembolic events in patients undergoing major surgery, such as orthopedic or abdominal procedures.
• Management of acute coronary syndromes, including unstable angina and non‑ST‑segment elevation myocardial infarction, when anticoagulation is indicated.
• Treatment of other thrombotic disorders as determined by a healthcare professional.

Adverse reactions to Heparibene Na vary in frequency and severity; they are classified as common or serious.

Common

• Minor bleeding at the injection site.
• Nosebleeds (epistaxis).
• Hematuria (blood in urine).
• Mild thrombocytopenia (reduced platelet count).

Serious

• Major hemorrhage, including intracranial or gastrointestinal bleeding.
• Heparin‑induced thrombocytopenia (HIT) with risk of thrombosis.
• Allergic reactions such as rash, urticaria, or anaphylaxis.
• Elevated liver enzymes indicating hepatic injury.

Before initiating Heparibene Na, clinicians should evaluate several precautionary factors to minimize risk.

• Assess patient history for bleeding disorders, recent surgery, or trauma.
• Review renal and hepatic function, as impairment may affect drug clearance.
• Monitor platelet counts regularly to detect heparin‑induced thrombocytopenia.
• Use caution in pregnant or lactating women; benefits must outweigh potential risks.
• Avoid concurrent use of other anticoagulants or antiplatelet agents unless specifically indicated.
• Adjust dose in patients with severe obesity or low body weight under medical guidance.
• Ensure appropriate laboratory monitoring (e.g., activated partial thromboplastin time) during therapy.

Heparibene Na may interact with other medications, altering its anticoagulant effect or increasing bleeding risk.

Avoid

• Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) without careful monitoring.
• Combination with antiplatelet drugs such as aspirin, clopidogrel, or non‑steroidal anti‑inflammatory drugs (NSAIDs).

Use with caution

• Concurrent administration of fibrinolytic agents (e.g., alteplase) due to additive bleeding risk.
• Use with certain antibiotics (e.g., vancomycin) that may potentiate anticoagulation.
• Concomitant therapy with corticosteroids or hormonal contraceptives that can affect coagulation parameters.